Takeda's once-monthly anaemia treatment accepted for EMA review
The drug, which was discovered by Affymax, is a potential new treatment for symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients on dialysis. If approved, Takeda will market the product alone in the EU, while in the US, ...
Takeda Announces Acceptance of European Marketing Authorisation Application ...SYS-CON Media (press release)
Search in our News ChannelsPipelineReview.com (press release)
Affymax to Receive $5 Million Milestone Payment for Acceptance of European ...MarketWatch (press release)
all 13 news articles »